An official website of the United States government

Publication Information

PubMed ID
Public Release Type
Journal
Publication Year
2015
Affiliation
The National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA.
Authors
Abdelmalek MF, Ackermann S, Ang B, Aouizerat B, Atla P, Barlow S, Bashir M, Bass NM, Behling C, Belt P, Bhatt A, Boyett S, Brandman D, Brown SR, Brunt EM, Buie S, Carucci L, Chalasani N, Clark JM, Contos MJ, Cooney S, Coy D, Croft B, Cummings OW, Dasarathy J, Dasarathy S, Diehl AM, Donithan M, Doo E, Doo EC, Ferrell LD, Fowler K, Garcia R, Garcia S, Gawrieh S, Gelinas K, Ghabril M, Gill R, Guy C, Hallinan E, Hameed B, Hawkins C, Hoofnagle JH, Isaacson M, Kigongo C, King D, Kleiner DE, Kowdley K, Kowdley KV, Kraft K, Lavine J, Lavine JE, Lee M, Loomba R, Luketic VA, Marri S, May KP, McCullough A, McCullough AJ, Middleton M, Miriel L, Molleston J, Mooney J, Murray K, NASH Clinical Research Network, Nelson JE, Neuschwander-Tetri B, Neuschwander-Tetri BA, Osmack P, Pagadala M, Pai R, Pan YP, Patton H, Pierce T, Piercy D, Puri P, Ragozzino L, Ramos C, Robuck PR, Rosenthal P, Sandrasegaran K, Sanyal A, Sanyal AJ, Sargent R, Schlosser J, Schwimmer J, Shaw C, Sheikh M, Sherker A, Siddique A, Siddiqui MS, Siegner J, Singh M, Sirlin C, Sternberg A, Stewart S, Terrault N, Tonascia J, Torrance RJ, Torretta S, Ünalp-Arida A, Ungermann A, Van Natta M, Van Natta ML, Vaughn I, Vuppalanchi R, Wang C, Whitington P, Wilson L, Wolford B, Xanthakos S, Yates K
Studies
Citation
Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, Chalasani N, Dasarathy S, Diehl AM, Hameed B, Kowdley KV, McCullough A, Terrault N, Clark JM, Tonascia J, Brunt EM, Kleiner DE, Doo E, NASH Clinical Research Network. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 2015 Mar 14;385(9972):956-65. Epub 2014 Nov 7.

Abstract

The bile acid derivative 6-ethylchenodeoxycholic acid (obeticholic acid) is a potent activator of the farnesoid X nuclear receptor that reduces liver fat and fibrosis in animal models of fatty liver disease. We assessed the efficacy of obeticholic acid in adult patients with non-alcoholic steatohepatitis.